Tempus AI (TEM) stock
Last close $54.04 on 2026-11-20 (-9.34%) · Sector: Healthcare
Tempus AI is a healthcare technology company that uses artificial intelligence and large amounts of medical data to help doctors choose treatments, with a focus on cancer care. It makes money mainly by selling genomic sequencing tests, which read a patient's genes, and by licensing its data and software to hospitals, doctors, and drug companies.
Sales are growing fast, with revenue up 37.3% over the past year, and the latest reported quarter was the strongest in the recent set. The company still loses money on an operating basis, with an operating margin of -18.5%, and the stock has fallen 29.0% over the past year while the S&P 500 rose 3.2%, so it has lagged the market. Insiders sold about $76.8 million of stock in the last 90 days and made no purchases, and the stock has moved up or down by several percent after its earnings releases.
Key numbers
- Revenue (last 12 months): $1.51B
- Revenue growth: +37.3%
- Operating margin: -18.5%
- Debt to equity: 0.00
- Current ratio: 2.59
Quality score
Overall 47/100 · growth 60 · profitability 0 · financial health 81 · value None
Performance and risk
1-year return -29.0% vs S&P 500 +3.1% · volatility 77.3% (S&P 500 14.2%) · largest drop -46.7% · beta 2.43
Stock move the day after earnings
- 2026-01-12: +4.5%
- 2026-02-24: -7.3%
- 2026-05-05: -1.1%
- 2026-07-30: -0.9%
- 2026-11-02: +8.7%
Insider trades (12 months)
Bought $0.0M · sold $196.0M
TEM stock research · TEM options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.